<DOC>
	<DOCNO>NCT02948959</DOCNO>
	<brief_summary>Primary Objective : To evaluate efficacy dupilumab child 6 &lt; 12 year age uncontrolled persistent asthma . Secondary Objectives : To evaluate child 6 &lt; 12 year age uncontrolled persistent asthma : - The safety tolerability dupilumab . - The effect dupilumab improve patient-reported outcome ( PROs ) . - The dupilumab systemic exposure incidence anti-drug antibody . - To explore association dupilumab treatment pediatric immune response vaccine : vaccination tetanus , diphtheria , pertussis and/or seasonal trivalent/quadrivalent influenza vaccine .</brief_summary>
	<brief_title>Evaluation Dupilumab Children With Uncontrolled Asthma ( Liberty Asthma Voyage )</brief_title>
	<detailed_description>The total study duration per patient 69 week , consist screening period 3-5 week , randomize treatment period 52 week post-treatment period 12 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>Inclusion criterion : Children 6 &lt; 12 year age , physician diagnosis persistent asthma ≥12 month prior Screening , base clinical history examination , pulmonary function parameter accord Global initiative asthma ( GINA ) 2015 Guidelines follow criterion : Existing background therapy mediumdose inhaled corticosteroid ( ICS ) second controller medication ( ie , longacting β2 agonist [ LABA ] , leukotriene receptor antagonist [ LTRA ] , long act muscarinic antagonist [ LAMA ] , methylxanthines ) highdose ICS alone high dose ICS second controller , least 3 month stable dose ≥1 month prior Screening Visit 1 . Prebronchodilator force expiratory volume 1 second ( FEV1 ) ≤95 % predict normal prebronchodilator FEV1/forced vital capacity ( FVC ) ratio &lt; 0.85 Screening Baseline Visits . Reversibility least 10 % FEV1 administration albuterol/salbutamol levalbuterol/levosalbutamol reliever medication randomization . Documented reversibility positive airway hyperresponsiveness methacholine within 12 month prior Screening V1 consider acceptable . Must experience within 1 year prior Screening Visit 1 follow event : Treatment systemic corticosteroid ( SCS , oral parenteral ) , prescribe healthcare professional worsening asthma least , Hospitalization emergency room visit worsen asthma . Evidence uncontrolled asthma , least one follow criterion 4 ( ±1 ) week Screening Period : Asthma Control QuestionnaireInterviewer Administered ( ACQIA ) ACQ5 score ≥1.5 least one day Screening Period . Use reliever medication ( ie , albuterol/salbutamol levalbuterol/levosalbutamol ) , preventive exercise induce bronchospasm , 3 day per week , least one week Screening Period . Sleep awaken due asthma symptom require use reliever medication least Screening Period . Asthma symptoms 3 day per week least one week Screening Period . Exclusion criterion : Patients &lt; 6 ≥12 year age . Patients &lt; 16 kg bodyweight . Any chronic lung disease ( cystic fibrosis , bronchopulmonary dysplasia , etc ) may impair lung function . A subject history life threaten asthma ( ie , extreme exacerbation require intubation ) . Comorbid disease might interfere evaluation investigational medicinal product ( IMP ) . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>